Board oversight of AI, but no published AI rules and little information on testing
Overall rating “limited”. No deduction for controversies. The superscript numbers link directly to the source.
1 · Responsibility
Oversight of AI is documented in the proxy statement, but a published AI policy or a described review procedure is missing; the programme is documented only through job postings.
What is documented
- The board's risk oversight covers the use of AI; the Science and Technology Committee oversees AI in research and development2
- The Audit Committee oversees information security and data protection and receives reports from the CISO2 1
- The CISO reports to the Chief Digital & Technology Officer1
- The 2026 code of conduct commits to responsible and ethical use of AI; the 2018 edition did not yet contain this4 8
- The 10-K mentions investment in AI upskilling and training on the responsible use of AI tools9
The case against
Programme documented only indirectly
Missing accountability
- Training rates, AI figures, a certification or an external audit of the AI programme are missing
- The Integrity Line is a general reporting channel; there is no AI-specific complaints channel with documented remedy4
Sources for Responsibility (12)
- Board Cybersecurity (board-cybersecurity.com): BRISTOL MYERS SQUIBB CO 10-K Item 1C. Cybersecurity – 2026-02-11 · 11 February 2026 · primary source
- Bristol-Myers Squibb Company (SEC EDGAR): Definitive Proxy Statement (DEF 14A) 2026, Annual Meeting 2026-05-05 · 25 March 2026 · primary source
- Mediabistro (Job Posting Bristol Myers Squibb): Senior Director, AI Governance, Law & Compliance (R1598558) · 3 November 2026 · secondary source
- Bristol-Myers Squibb Company: 2026 Principles of Integrity: BMS Standards of Business Conduct and Ethics · 1 January 2026 · secondary source
- Legal.io (Job Posting Bristol Myers Squibb): Counsel, AI Governance, Law and Compliance · 3 November 2026 · secondary source
- Bristol-Myers Squibb Company: Transparency & reporting · 3 November 2026 · secondary source
- Bristol-Myers Squibb Company: Position on key issues · 3 November 2026 · secondary source
- Bristol-Myers Squibb Company (über EthicsPoint): Principles of Integrity: Standards of Business Conduct and Ethics (edition 2/2018) · 1 February 2018 · secondary source
- Bristol-Myers Squibb Company (SEC EDGAR): Form 10-K for the fiscal year ended December 31, 2025 · 11 February 2026 · primary source
- Bristol-Myers Squibb Company: 2025 Impact Report · 31 December 2025 · secondary source
- Bristol-Myers Squibb Company: Privacy Notice (bms.com) · 3 November 2026 · secondary source
- Bristol-Myers Squibb Company (Kopie über Fortune/Quartr): Form 10-K FY2025 (PDF version) · 11 February 2026 · primary source
2 · Safety
BMS documents a cybersecurity programme assessed externally against NIST, but the validation of AI in pharmacovigilance remains open.
What is documented
- Item 1C describes an independent assessment against NIST every three years, an incident response plan with exercises and supplier risk management6
- The CPO and CISO run a joint data protection programme; the board is informed at least once a year6 7
- The WEF recognised the Devens site with more than 30 digital and AI applications as a Lighthouse4
- In Devens and in “Predict First”, specialists make the final decision on AI recommendations3 2
The case against
Missing evidence of AI testing
Incident at a service provider
- In 2024, health data of customers of BMS programmes was stolen at distributor Cencora; according to the report, BMS systems were not affected10
- Protective measures for models, training data and access by AI agents are not disclosed
Sources for Safety (10)
- Bristol-Myers Squibb Company: 2025 Impact Report · 31 December 2025 · secondary source
- PharmaVoice (Alexandra Pecci): How Bristol Myers Squibb uses AI to validate drugs before the lab («Predict First») · 24 July 2025 · secondary source
- The New York Times (Farah Stockman), reprinted in The Star: American factories lag in adopting AI. This drugmaker is an exception. · 9 May 2026 · secondary source
- World Economic Forum: Global Lighthouse Network Recognizes 23 New Sites, Launches AI Platform for Industrial Transformation · 15 January 2026 · primary source
- AuntMinnie: Bristol Myers Squibb, Microsoft partner on early lung cancer detection · 20 January 2026 · secondary source
- Board Cybersecurity (board-cybersecurity.com): BRISTOL MYERS SQUIBB CO 10-K Item 1C. Cybersecurity – 2026-02-11 · 11 February 2026 · primary source
- Bristol-Myers Squibb Company (SEC EDGAR): Definitive Proxy Statement (DEF 14A) 2026, Annual Meeting 2026-05-05 · 25 March 2026 · primary source
- Bristol-Myers Squibb Company: 2026 Principles of Integrity: BMS Standards of Business Conduct and Ethics · 1 January 2026 · secondary source
- Mediabistro (Job Posting Bristol Myers Squibb): Senior Director, AI Governance, Law & Compliance (R1598558) · 3 November 2026 · secondary source
- TEISS: Pharmaceuticals firm Cencora says data breach impacted Bristol Myers Squibb customers · 23 May 2024 · secondary source
3 · Transparency
BMS describes its AI applications publicly but publishes no performance limits, error rates, validation results or model information for any of its own systems.
What is documented
- The Impact Report and specialist articles describe AI in research, clinical development, manufacturing and drug safety2 4 5
- The privacy notice mentions AI-supported candidate selection with a final human decision and possible automated decisions3
- Transparency and ethical oversight of AI are named as principles in the Impact Report and the code of conduct2 6
The case against
Missing system information
Missing information for those affected
- Whether patients and physicians are informed about the use of AI is not documented
- No register of the AI systems in use was found
Sources for Transparency (9)
- Bristol-Myers Squibb Company (SEC EDGAR): Form 10-K for the fiscal year ended December 31, 2025 · 11 February 2026 · primary source
- Bristol-Myers Squibb Company: 2025 Impact Report · 31 December 2025 · secondary source
- Bristol-Myers Squibb Company: Privacy Notice (bms.com) · 3 November 2026 · secondary source
- PharmaVoice (Alexandra Pecci): How Bristol Myers Squibb uses AI to validate drugs before the lab («Predict First») · 24 July 2025 · secondary source
- Bristol-Myers Squibb Company: Accelerating protein degradation science with AI and machine learning · 31 July 2024 · secondary source
- Bristol-Myers Squibb Company: 2026 Principles of Integrity: BMS Standards of Business Conduct and Ethics · 1 January 2026 · secondary source
- The New York Times (Farah Stockman), reprinted in The Star: American factories lag in adopting AI. This drugmaker is an exception. · 9 May 2026 · secondary source
- Intelligent CIO: Bristol Myers Squibb builds AI factory with NVIDIA to accelerate drug discovery · 31 July 2026 · secondary source
- Bristol-Myers Squibb Company: Bioethics policy statement · 3 November 2026 · secondary source
4 · Why the harm rule does not apply
The harm rule does not apply: in the research period no judgment, no authority decision, no fine and no pattern of harm from BMS's use of AI was found.
5 · Controversies (1)
6 · What remains open
- Public AI policy, risk classes and approval procedures for in-house and purchased AI
- Implementation status of the AI governance framework with model inventory, reviews and figures
- Validation and monitoring of AI in pharmacovigilance and manufacturing
- AI-related risk factors and legal proceedings from Items 1A and 3 of the 10-K, which were not readable
- FDA primary evidence of the clearance of the radiology algorithms
- Model or system cards and information on the limitations of its own models
7 · How it was assessed
Cut-off date: 3 November 2026 · 42 searches, 31 fetches.
Primary documents read (11)
- Form 10-K FY2025 (Item 1 through start of Item 1A, Human Capital)
- Item 1C Cybersecurity 10-K FY2025 (via reproduction S02)
- Proxy Statement DEF 14A 2026 (through Director Compensation, two retrievals)
- DEFA14A Proxy Season Update 2025
- Form 8-K Voting Results 2026
- Form 10-Q Q1 and Q3 2026 (Notes, partial)
- 2025 Annual Report (ARS), Shareholder Letter
- 2025 Impact Report (pp. 1–44)
- 2026 Principles of Integrity and 2018 Edition
- Privacy Notice bms.com (partial)
- Bioethics policy statement
Research of 3 November 2026 under Globalance AI Footprint rulebook version 0